Product & Industry News
Page 1 to 16 of 106 |     NEXT PAGE >
ELRIG announces Drug Discovery Digital 3 July 2020 Image: Theme Photos
Due to the restrictions imposed by the global COVID-19 pandemic, ELRIG's 14th Drug Discovery, will be a virtual event.

Read More

My Personal Therapeutics and Pentavere scoop funding for lung cancer digital therapeutics 3 July 2020 Image: Japeth Mast
My Personal Therapeutics and Pentavere Research Group, have achieved EUREKA Collaborative R&D: AI and Quantum Technologies Competition success for their project Utilisation of AI to develop Personalised Treatment Plans for cancer.

Read More

Orexo launches deprexis and vorvida digital therapies in the US 3 July 2020 Image: Ashwin Vaswani
In the US Orexo has launched the digital therapies deprexis and vorvida, for the treatment of depression and management of alcohol misuse respectively.

Read More

Abivax treats first patient in COVID-19 clinical trial in France 3 July 2020 Image: Sharon McCutcheon
The first patient has been treated in Abivax's Phase IIa/III study of ABX464 in COVID-19 patients at the University Hospital Centre in Nice, France.

Read More

FDA approves ViiV Healthcare's Rukobia for HIV in adults 3 July 2020 Image: Halacious
The FDA has approved ViiV Healthcare's Rukobia (fostemsavir), 600mg extended-release tablets for adults who cannot be treated with other therapies due to resistance, intolerance or safety considerations.

Read More

Sanofi and Regeneron stop Kevzara COVID-19 trial in US 3 July 2020 Image: SJ Objio
Sanofi and Regeneron Pharmaceuticals have announced that the US Phase III trial of rheumatoid arthritis drug Kevzara (sarilumab) in COVID-19 patients requiring mechanical ventilation did not meet its main goals.

Read More

DDW summer issue now out 2 July 2020
From the race to the COVID-19 cure to the new manufacturing technologies that could be a game changer for stem cell therapies.

Read More

EUSA Pharma receives FDA approval of phase III clinical trial for siltuximab 2 July 2020 Image: Nino Liverani
The US Food & Drug Administration (FDA) has approved a randomised, double-blind, placebo-controlled phase III clinical trial protocol to evaluate the safety and efficacy of intravenous siltuximab.

Read More

ViiV Healthcare to present new HIV data at International AIDS Conference 2 July 2020 Image: Shayna Douglas
Continuing to challenge the current HIV treatment paradigm, data presented will investigate new and innovative treatment options for people living with HIV.

Read More

Symbiosis secures £1 million of growth finance from Allied Irish Bank 1 July 2020 Image: Micheile Henderson
Symbiosis Pharmaceutical Services has secured £1million of finance from Allied Irish Bank (GB) to support its 2020 growth strategy.

Read More

Alnylam reports new data on study of givosiran in acute hepatic porphyria 1 July 2020 Image: CDC
Alnylam Pharmaceuticals has new data from the open-label extension (OLE) period of the ENVISION Phase 3 study

Read More

Clinical trial examines alpha-1-antitrypsin for severe COVID-19 infection 1 July 2020 Image: Robina Weermeijer
Clinician scientists at RCSI University of Medicine and Health Sciences, Ireland, have begun a clinical trial of a promising therapy for critically ill COVID-19 patients in intensive care.

Read More

New paper published on gene editing technique in hematopoietic stem cells 30 June 2020 Image: National Cancer Institute
The San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) and Genespire have published data highlighting progress in the development of an improved targeted gene replacement technology in human hematopoietic stem cells (HSCs) in Nature Biotechnology.

Read More

PharmEnable raises £1.8 million for drug discovery expansion 30 June 2020 Image: Lucas Vasques
PharmEnable, has closed a £1.8 million seed financing to support its transition into a drug development company.

Read More

Engineers use 'DNA origami' to identify vaccine design rules 30 June 2020 Image: Glen Carrie
In lab tests, virus-like DNA structures coated with viral proteins provoke a strong immune response in human B cells, by Ann Trafton, MIT News Office

Read More

PARP inhibitor could be effective treatment for high-risk childhood neuroblastoma 29 June 2020 Image: National Cancer Institute
A type of drug already used to treat breast and ovarian cancer, called a PARP inhibitor, may be useful in treating children with high-risk neuroblastoma, a childhood tumour with a low survival rate, a new study suggests.

Read More

Product & Industry News
Page 1 to 16 of 106 |     NEXT PAGE >